Publications

57th Annual Meeting of the American Society of Hematology (ASH) (December 5 – 8, 2015)

Click an abstract title below to view:

Abstract 1: Evaluation of Purified Poloxamer-188 (vepoloxamer) on Sickle Red Blood Cell (RBC) Membrane Function Properties
Abstract 2: Characterizing Cellular Interactions Contributing to Vaso-Occlusion in Patients with Sickle Cell Disease Utilizing a Novel Endothelialized Microfluidic Device
Abstract 3: Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188 ) As Studied in Agonist Induced Platelet Aggregation Systems


American Heart Association’s (AHA) Scientific Sessions (November 7-11, 2015)

Effect of Repeat Intravenous Infusion of Vepoloxamer (Purified Poloxamer 188) on Left Ventricular Systolic Function in Dogs with Advanced Heart Failure
Presented by Dr. Hani N. Sabbah, Professor of Medicine and Director of Cardiovascular Research at Henry Ford Health System


19th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) (Sept 26-29, 2015)

In-Vitro Exposure of Isolated Failing Cardiomyocytes to Vepoloxamer (Purified Poloxamer 188) Limits Unregulated Calcium Entry into the Cell
Presented by Dr. Hani N. Sabbah, Professor of Medicine and Director of Cardiovascular Research at Henry Ford Health System


9th Annual Sickle Cell Disease Research and Educational Symposium (April 10 – 13, 2015)

Evaluation of purified poloxamer-188 (vepoloxamer) on sickle red blood cell (RBC) adhesion and membrane fragility utilizing microfluidic-based flow adhesion bioassays


International Stroke Conference 2015 (February 11 – 13, 2015)

Combination of Vepoloxamer and tPA extends the therapeutic window of stroke


56th Annual Meeting of the American Society of Hematology (ASH) (December 6 – 9, 2014)

Pro-coagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and their Modulation by a Triblock Polymer MST 188


American Heart Association (AHA) Scientific Sessions 2014 (November 19, 2014)

Short (2 hour) Intravenous Infusion of Vepoloxamer (MST-188) Elicits Prolonged (1-2 weeks) Improvement in Biomarkers in Dogs with Advanced Heart Failure


8th Annual Sickle Cell Disease Research & Educational Symposium (April 11, 2014)

Effect of Purified Poloxamer 188 or Various Dextrans on Erythrocyte Sedimentation Rate in Patients with Sickle Cell Disease


National Institutes of Health Annual Sickle Cell Disease Research Clinical Meeting (August 21, 2013)

EPIC – An Ongoing Pivotal Phase 3 Study in Patients with Sickle Cell Disease


7th Annual Sickle Cell Disease Research & Educational Symposium (April 17, 2013)

Is There a Role for a Rheologic Agent in Transfusion?
Poster presented by R. Martin Emanuele, Ph.D., Senior Vice President, Development

Evaluation of Purified Poloxamer 188 in Children (EPIC) – Key Design Considerations
Poster presented by Santosh J. Vetticaden, Ph.D., M.D., Chief Medical Officer

 

 

News

Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more

Technology

Click here to learn more about our lead product candidate, vepoloxamer.
  read more

Clinical Trials

We have initiated a Phase 3 clinical study of vepoloxamer for the treatment of sickle cell disease. Click here for more info. read more